Oct. 29, 2025 – denosumab-desu (Jubereq) BLA approval; the 120 mg/1.7 mL single-dose vial for SC use has received FDA approval as an interchangeable biosimilar to the same presentation of denosumab...

From next-gen CFTR modulators to gene therapy and real-world drug impact, cystic fibrosis care is constantly evolving. Maryam Tabatabai, PharmD, of Prime Therapeutics, explains how innovative...

New biosimilars Feb. 26, 2026 – zongertinib (Hernexeos) Boehringer Ingelheim; kinase inhibitor; Accelerated Approval, Assessment Aid, Breakthrough Therapy, Commissioner's National Priority Voucher...

Prime Therapeutics Report shares more about single-treatment gene therapies and proper management